Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: A population-based cohort study of all patients in western Sweden with long-term follow-up

Acta Obstetricia et Gynecologica Scandinavica

Volumn 87, Issue 12, 2008, Pages 1343-1352

  Åkeson, Margaretha ^a,b   Zetterqvist, Britt Marie ^c   Dahllöf, Kalle ^d   Brännström, Mats ^e   Horvath, György ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Division of Obstetrics and Gynecology   (Sweden)

^c Division of Obstetrics and Gynecology   (Sweden)

^d Regional Oncologic Centre   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Long term survival; Ovarian cancer; Paclitaxel; Prognostic factors; Surgical centralization

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; EPITHELIUM; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SWEDEN;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; SURVIVAL RATE; SWEDEN;

EID: 57449093837     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340802495491     Document Type: Article

References (46)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. The National Board of Health and Welfare, Centre for Epidemiology. Cancer incidence in Sweden 2005. Stockholm: Socialstyrelsen and Official Statistics of Sweden; 2007.
3. Beral V, Doll R, Hermon C, Peto R, Reeves G; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303-14.
4. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120-7.
5. Brenner H, Hakulinen T. Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry. Br J Cancer. 2001;85:367-71.
6. Gatta G, Capocaccia R, Coleman MP, Gloeckler Ries LA, Hakulinen T, Micheli A, et al. Toward a comparison of survival in American and European cancer patients. Cancer. 2000;89:893-900.
7. Lambert HE, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 2004;14:772-8.
8. Oksefjell H, Sandstad B, Trope C. Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001. Eur J Gynaecol Oncol. 2007;28:256-62.
9. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO Sixth Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S161-92.
10. Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists Group. Br J Cancer. 1998;78:1479-87.
11. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
12. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699-708.
13. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the Lancet. 2002;360:505-15.
14. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106-15.
15. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2006CD005340.
16. Akeson M, Zetterqvist BM, Holmberg E, Horvath G. Improved survival with clinical guidelines? Evaluation of a quality register linked to clinical guidelines for ovarian cancer in the western health care region in Sweden between 1 September 1993 and 1 June 1998. Acta Obstet Gynecol Scand. 2005;84:1113-8.
17. Hiddemann W, Schumann J, Andreef M, Barlogie B, Herman CJ, Leif RC, et al. Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet. 1984;13:181-3.
18. Lee GM, Thornthwaite JT, Rasch EM. Picogram per cell determination of DNA by flow cytofluorometry. Anal Biochem. 1984;137:221-6.
19. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Gynecol Oncol. 1992;79:1002-10.
20. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Gynecol Oncol. 1995;86:259-64.
21. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260:103-17.
22. Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comput Programs Biomed. 1985;19:197-207.
23. Soegaard Andersen E, Knudsen A, Svarrer T, Lund B, Nielsen K, Grove A, et al. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecol Oncol. 2005;99:552-6.
24. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol. 2003;102:499-505.
25. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol. 2005;99:447-61.
26. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77-85.
27. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559-64.
28. Skirnisdottir I, Sorbe B. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. Int J Oncol. 2007;30:727-34.
29. Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer. 2002;87:815-24.
30. Hilpert F, du Bois A, Greimel ER, Hedderich J, Krause G, Venhoff L, et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged > or =70 years with advanced ovarian cancer - a study by the AGO OVAR Germany. Ann Oncol. 2007;18:282-7.
31. Tredan O, Geay JF, Touzet S, Delva R, Weber B, Cretin J, et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l Etude des Cancers Ovariens. Ann Oncol. 2007;18:256-62.
32. Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group Experience. Cancer. 1993;71:606-14.
33. Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95:1314-20.
34. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer. 2001;85:944-52.
35. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108:521-8.
36. Trope C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol. 2007;25:2909-20.
37. Trope C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Ann Oncol. 2000;11:281-8.
38. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-59.
39. Kumpulainen S, Grenman S, Kyyronen P, Pukkala E, Sankila R. Evidence of benefit from centralised treatment of ovarian cancer: a nationwide population-based survival analysis in Finland. Int J Cancer. 2002;102:541-4.
40. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16 Suppl 1:11-7.
41. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97:922-9.
42. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93:448-52.
43. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535-8.
44. Hogberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol. 1993;48:38-49.
45. Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-7.
46. Makar AP, Baekelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995;56:175-80.